Ascendis Pharma price target raised to $250 from $245 at RBC Capital

RBC Capital raised the firm’s price target on Ascendis Pharma (ASND) to $250 from $245 and keeps an Outperform rating on the shares after meeting with its management team. On Yorvipath, Ascendis emphasizes that they anticipate that the launch momentum to continue in 2026 steadily, the analyst tells investors in a research note. Ascendis also notes that the market remains largely under penetrated in the U.S., discontinuation rate remains low, and the opportunity in the EU remains very meaningful, the firm added.